Evidence map›Paper›PMID 34169368›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2021

Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE study.

Jonathan Vigne, Damien Peyronnet, Julien Leenhardt, Constance Dubegny, Valérie Ardisson, Guillaume Pariscoat, Claire Bolot, Aurore Rauscher, François Hallouard, Caroline Clave-Darcissac and 7 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jonathan VigneDepartment of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000, Caen, France. vigne-jo@chu-caen.fr.ORCID http://orcid.org/0000-0002-6575-9224
Damien PeyronnetDepartment of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000, Caen, France.
Julien LeenhardtNuclear Medicine Department, Grenoble-Alpes University Hospital, Grenoble, France.
Constance DubegnyRadiopharmacy, Nuclear Medicine Department, CHU de Nantes, 44000, Nantes, France.
Valérie ArdissonDepartment of Pharmacy, Centre de lutte contre le cancer Eugène Marquis, 35000, Rennes, France.
Guillaume PariscoatDepartment of Nuclear Medicine, CHU Bichat, Assistance Publique Hôpitaux de Paris, 75018, Paris, France.
Claire BolotRadiopharmacy Unit, Pharmacy Department, Groupement Hospitalier Est, Hospices Civils de Lyon, 59 boulevard Pinel, 69677, Bron Cedex, France.
Aurore RauscherRadiopharmacy, Nuclear Medicine Department, ICO Nantes-Angers, 44800, Saint-Herblain, France.
François HallouardRadiopharmacy Unit, Pharmacy Department, Groupement Hospitalier Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69310, Pierre-Bénite, France.
Caroline Clave-DarcissacRadiopharmacy Unit, Pharmacy Department, Groupement Hospitalier Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69310, Pierre-Bénite, France.
Anthony ClotagatideDepartment of Pharmacy, CHU de Saint-Etienne, Hôpital Nord, 42055, Saint-Etienne, France.
Emmanuel OdouardDepartment of Pharmacy, CHU de Saint-Etienne, Hôpital Nord, 42055, Saint-Etienne, France.
Alain Faivre-ChauvetRadiopharmacy, Nuclear Medicine Department, CHU de Nantes, 44000, Nantes, France.
Justine DiehlBiostatistic and Clinical Research, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000, Caen, France.
Benjamin HouduDepartment of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000, Caen, France.
Denis AgostiniDepartment of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000, Caen, France.
Rémy MorelloBiostatistic and Clinical Research, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000, Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe coronavirus disease 2019 (COVID-19) pandemic reshaped the usual risk: benefit equilibrium that became a trade-off between the infection exposure risk for the patient (and for staff) and the risk associated with delaying or cancelling the nuclear medicine examination. This study aimed at quantifying the impact of the first COVID-19 lockdown in France on nuclear medicine examination volume together with volume of examination cancellation and non-attendance.

methodsWe retrospectively assessed the volume of planned examinations from 1 month before to 1 month after the first lockdown in French high-volume nuclear medicine departments (NMD) sharing the same information management system including both university hospitals, UH (n = 7), and cancer centres, CC (n = 2).

resultsThe study enrolled 31,628 consecutive patients referred for a nuclear medicine examination performed or not (NMEP or NMEnP). The total volume of NMEP significantly dropped by 43.4% between the 4 weeks before and after the starting of the lockdown. The comparison of the percentage of NMEP and NMEnP between UH and CC is significantly different (p < 0.001). The percentage of NMEP during the study was 67.9% in UH vs 84.7% in CC. Percentages of NMEnP in UH and CC were due respectively to cancellation by the patient (14.9 vs 7.4%), cancellation by the NMD (9.5 vs 3.4%), cancellation by the referring physician (5.1 vs 4.4%) and non-attender patients (2.7 vs 0.2%).

conclusionThe study underlines the public health issue caused by COVID-19 above the pandemic itself and should be useful in preparing for potential resource utilisation and staffing requirements.

Indexed as

COVID-19Nuclear MedicineCommunicable Disease ControlFranceHumansRetrospective StudiesSARS-CoV-2COVID-19LockdownNuclear medicinePublic health

Identifiers

PMID34169368
PMCPMC8224993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.